常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.98/-0.62
|
|
企業價值
7.76M
|
| 資產負債 |
|
每股賬面淨值
0.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.74M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 15:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |

0.9206 
